{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:16:45Z","timestamp":1783142205065,"version":"3.54.6"},"reference-count":134,"publisher":"The Society for Free Radical Research Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.3164\/jcbn.25-259","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:08:18Z","timestamp":1773871698000},"page":"1-14","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic insights and evidence-based management of metabolic dysfunction-associated steatotic liver disease (MASLD; formerly NAFLD) through combined diet and exercise interventions: an evidence-based narrative review"],"prefix":"10.3164","volume":"79","author":[{"given":"Yuanyuan","family":"Chen","sequence":"first","affiliation":[{"name":"Nutritional Department, Jianyang Women and Children\u2019s Hospital, Chengdu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqin","family":"Liu","sequence":"additional","affiliation":[{"name":"Nutritional Department, Jianyang Women and Children\u2019s Hospital, Chengdu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renli","family":"Huang","sequence":"additional","affiliation":[{"name":"Nutritional Department, Jianyang Women and Children\u2019s Hospital, Chengdu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinwei","family":"Li","sequence":"additional","affiliation":[{"name":"Nutritional Department, Jianyang Women and Children\u2019s Hospital, Chengdu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nutritional Department, Jianyang Women and Children\u2019s Hospital, Chengdu"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Cataldo I, Sarcognato S, Sacchi D, et al. Pathology of non-alcoholic fatty liver disease. Pathologica 2021; 113: 194\u2013202.","DOI":"10.32074\/1591-951X-242"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J 2020; 50: 1038\u20131047.","DOI":"10.1111\/imj.14709"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ezpeleta M, Gabel K, Cienfuegos S, et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: a randomized controlled trial. Cell Metab 2023; 35: 56\u201370.e3.","DOI":"10.1016\/j.cmet.2022.12.001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord 2022; 22: 63.","DOI":"10.1186\/s12902-022-00980-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Zelman S. The liver in obesity. Arch Intern Med 1952; 90: 141\u2013156.","DOI":"10.1001\/archinte.1952.00240080007002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434\u2013438.","DOI":"10.1016\/S0025-6196(24)00530-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020; 73: 202\u2013209.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79: 1542\u20131556.","DOI":"10.1097\/HEP.0000000000000696"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol 2023; 29 (suppl): S5\u2013S16.","DOI":"10.3350\/cmh.2022.0424"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Malnick SDH, Alin P, Somin M, Neuman MG. Fatty liver disease-alcoholic and non-alcoholic: similar but different. Int J Mol Sci 2022; 23: 16226.","DOI":"10.3390\/ijms232416226"},{"key":"11","unstructured":"11 Fan JG, Xu XY, Yang RX, et al. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024). J Clin Transl Hepatol 2024; 12: 955\u2013974."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Park J, Zhao Y, Zhang F, et al. IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J Hepatol 2023; 78: 45\u201356.","DOI":"10.1016\/j.jhep.2022.08.022"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Xue WY, Zhang L, Liu CM, et al. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2022; 16: 97\u2013107.","DOI":"10.1080\/17474124.2022.2032661"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Rashu EB, Werge MP, Hetland LE, et al. Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population. Clin Res Hepatol Gastroenterol 2024; 48: 102389.","DOI":"10.1016\/j.clinre.2024.102389"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Mana MF, Parisi MCR, Correa-Giannella ML, et al. Non-alcoholic fatty liver disease in long-term type 2 diabetes: role of rs738409 <i>PNPLA3<\/i> and rs499765 <i>FGF21<\/i> polymorphisms and serum biomarkers. Molecules 2022; 27: 3193.","DOI":"10.3390\/molecules27103193"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Basu Ray S. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte 2019; 8: 201\u2013208.","DOI":"10.1080\/21623945.2019.1607423"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Zhao J, Lei H, Wang T, Xiong X. Liver-bone crosstalk in non-alcoholic fatty liver disease: clinical implications and underlying pathophysiology. Front Endocrinol (Lausanne) 2023; 14: 1161402.","DOI":"10.3389\/fendo.2023.1161402"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Li HY, Huang SY, Zhou DD, et al. Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis. J Adv Res 2023; 52: 59\u201372.","DOI":"10.1016\/j.jare.2023.01.008"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Pirola CJ, Sookoian S. Non-alcoholic fatty liver disease mediates the effect of obesity on arterial hypertension. Liver Int 2023; 43: 2167\u20132176.","DOI":"10.1111\/liv.15643"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Rajaram RB, Jayaraman T, Yoong BK, et al. Non-alcoholic fatty liver disease and obesity among adult donors are major challenges to living-donor liver transplantation: a single-center experience. Asian J Surg 2022; 45: 441\u2013447.","DOI":"10.1016\/j.asjsur.2021.07.046"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Wei L, Li M, Zeng N, et al. Bariatric surgery for non-alcoholic fatty liver disease in individuals with obesity (Base-NAFLD): protocol of a prospective multicenter observational follow-up study. BMC Surg 2021; 21: 298.","DOI":"10.1186\/s12893-021-01296-y"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Roy PP, Mahtab MA, Rahim MA, Yesmin SS, Islam SB, Akbar SMF. Treatment of nonalcoholic steatohepatitis by obeticholic acid: current status. Euroasian J Hepatogastroenterol 2022; 12 (Suppl 1): S46\u2013S50.","DOI":"10.5005\/jp-journals-10018-1360"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024; 390: 497\u2013509.","DOI":"10.1056\/NEJMoa2309000"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Sven MF, Pierre B, Manal FA, et al. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study. Contemp Clin Trials 2020; 98: 106170.","DOI":"10.1016\/j.cct.2020.106170"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Romero-G\u00f3mez M, Lawitz E, Shankar RR, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol 2023; 79: 888\u2013897.","DOI":"10.1016\/j.jhep.2023.05.013"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Maleki Sedgi F, Mohammad Hosseiniazar M, Alizadeh M. The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance and anthropometric measurements in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial. Br J Nutr 2024; 131: 1985\u20131996.","DOI":"10.1017\/S0007114524000564"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 George ES, Reddy A, Nicoll AJ, et al. Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: the MEDINA randomised controlled trial. Liver Int 2022; 42: 1308\u20131322.","DOI":"10.1111\/liv.15264"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Alami F, Alizadeh M, Shateri K. The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Scand J Gastroenterol 2022; 57: 1238\u20131249.","DOI":"10.1080\/00365521.2022.2071109"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Dai L, Xu J, Liu B, et al. Lingguizhugan decoction, a Chinese herbal formula, improves insulin resistance in overweight\/obese subjects with non-alcoholic fatty liver disease: a translational approach. Front Med 2022; 16: 745\u2013759.","DOI":"10.1007\/s11684-021-0880-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Navyasree KV, Ramesh ST, Umasankar PK. Cholesterol regulates insulin-induced mTORC1 signaling. J Cell Sci 2023; 136: jcs261402.","DOI":"10.1242\/jcs.261402"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Lee G, Kim YY, Jang H, et al. SREBP1c-PARP1 axis tunes anti-senescence activity of adipocytes and ameliorates metabolic imbalance in obesity. Cell Metab 2022; 34: 702\u2013718.e5.","DOI":"10.1016\/j.cmet.2022.03.010"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Dai J, Jiang M, Hu Y, et al. Dysregulated SREBP1c\/miR-153 signaling induced by hypertriglyceridemia worsens acute pancreatitis and delays tissue repair. JCI Insight 2021; 6: e138584.","DOI":"10.1172\/jci.insight.138584"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Chen T, Dalton G, Oh SH, et al. Hepatocyte smoothened activity controls susceptibility to insulin resistance and nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol 2023; 15: 949\u2013970.","DOI":"10.1016\/j.jcmgh.2022.12.008"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 R\u00e9gnier M, Carbinatti T, Parlati L, Benhamed F, Postic C. The role of ChREBP in carbohydrate sensing and NAFLD development. Nat Rev Endocrinol 2023; 19: 336\u2013349.","DOI":"10.1038\/s41574-023-00809-4"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Arconzo M, Piccinin E, Moschetta A. Increased risk of acute liver failure by pain killer drugs in NAFLD: focus on nuclear receptors and their coactivators. Dig Liver Dis 2021; 53: 26\u201334.","DOI":"10.1016\/j.dld.2020.05.034"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Wang J, Li J, Fu Y, Zhu Y, Lin L, Li Y. Research progress, challenges and perspectives of phospholipids metabolism in the LXR-LPCAT3 signaling pathway and its relation to NAFLD (Review). Int J Mol Med 2024; 53: 32.","DOI":"10.3892\/ijmm.2024.5356"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Peng Z, Gong Y, Wang X, et al. METTL3-m<sup>6<\/sup>A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease. Mol Ther 2022; 30: 932\u2013946.","DOI":"10.1016\/j.ymthe.2021.09.016"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908\u2013922.","DOI":"10.1038\/s41591-018-0104-9"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Mardinoglu A, Wu H, Bjornson E, et al. An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. Cell Metab 2018; 27: 559\u2013571.e5.","DOI":"10.1016\/j.cmet.2018.01.005"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278\u20131283.","DOI":"10.1136\/gut.2011.242073"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Petrescu M, Vlaicu SI, Cium\u0103rnean L, et al. Chronic inflammation-A link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue. Medicina (Kaunas) 2022; 58: 641.","DOI":"10.3390\/medicina58050641"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Zhang CH, Zhou BG, Sheng JQ, Chen Y, Cao YQ, Chen C. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res 2020; 159: 104984.","DOI":"10.1016\/j.phrs.2020.104984"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Lu S, Li Y, Qian Z, et al. Role of the inflammasome in insulin resistance and type 2 diabetes mellitus. Front Immunol 2023; 14: 1052756.","DOI":"10.3389\/fimmu.2023.1052756"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 de Deus IJ, Martins-Silva AF, Fagundes MMA, et al. Role of NLRP3 inflammasome and oxidative stress in hepatic insulin resistance and the ameliorative effect of phytochemical intervention. Front Pharmacol 2023; 14: 1188829.","DOI":"10.3389\/fphar.2023.1188829"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Yu L, Hong W, Lu S, et al. The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment. Front Pharmacol 2022; 13: 780496.","DOI":"10.3389\/fphar.2022.780496"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Sundaram SS, Halbower A, Pan Z, et al. Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease. J Hepatol 2016; 65: 560\u2013569.","DOI":"10.1016\/j.jhep.2016.04.010"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Weng JR, Bai LY, Chiu CF, Wang YC, Tsai MH. The dietary phytochemical 3,3&apos;-diindolylmethane induces G2\/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF-\u03baB, MAPK, and p53 signaling. Chem Biol Interact 2012; 195: 224\u2013230.","DOI":"10.1016\/j.cbi.2012.01.003"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015; 21: 739\u2013746.","DOI":"10.1016\/j.cmet.2015.04.004"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Yao N, Yang Y, Li X, et al. Effects of dietary nutrients on fatty liver disease associated with metabolic dysfunction (MAFLD): based on the intestinal-hepatic axis. Front Nutr 2022; 9: 906511.","DOI":"10.3389\/fnut.2022.906511"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Yang JM, Sun Y, Wang M, et al. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25: 5105\u20135119.","DOI":"10.3748\/wjg.v25.i34.5105"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Hui D, Liu L, Azami NLB, et al. The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial. Front Endocrinol (Lausanne) 2023; 13: 1107071.","DOI":"10.3389\/fendo.2022.1107071"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63: 764\u2013775.","DOI":"10.1002\/hep.28356"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Zhang C, Zhang H, Yu L, Cao Y. <i>Helicobacter pylori<\/i> dwelling on the apical surface of gastrointestinal epithelium damages the mucosal barrier through direct contact. Helicobacter 2014; 19: 330\u2013342.","DOI":"10.1111\/hel.12138"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Heimesaat MM, Fischer A, Plickert R, et al. <i>Helicobacter pylori<\/i> induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils. PLoS One 2014; 9: e100362.","DOI":"10.1371\/journal.pone.0100362"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Khosravi Y, Seow SW, Amoyo AA, et al. <i>Helicobacter pylori<\/i> infection can affect energy modulating hormones and body weight in germ free mice. Sci Rep 2015; 5: 8731.","DOI":"10.1038\/srep08731"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Frost F, Kacprowski T, R\u00fchlemann M, et al. <i>Helicobacter pylori<\/i> infection associates with fecal microbiota composition and diversity. Sci Rep 2019; 9: 20100.","DOI":"10.1038\/s41598-019-56631-4"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Peng C, Xu X, He Z, et al. <i>Helicobacter pylori<\/i> infection worsens impaired glucose regulation in high-fat diet mice in association with an altered gut microbiome and metabolome. Appl Microbiol Biotechnol 2021; 105: 2081\u20132095.","DOI":"10.1007\/s00253-021-11165-6"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Guo Y, Xu C, Gong R, et al. Exosomal CagA from <i>Helicobacter pylori<\/i> aggravates intestinal epithelium barrier dysfunction in chronic colitis by facilitating Claudin-2 expression. Gut Pathog 2022; 14: 13.","DOI":"10.1186\/s13099-022-00486-0"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med 2024; 19: 275\u2013293.","DOI":"10.1007\/s11739-023-03374-w"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Oh TG, Kim SM, Caussy C, et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab 2020; 32: 878\u2013888.e6.","DOI":"10.1016\/j.cmet.2020.06.005"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Li Z, Zhang B, Liu Q, et al. Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease. EBioMedicine 2023; 90: 104543.","DOI":"10.1016\/j.ebiom.2023.104543"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Ghanem SE, Elsabaawy MM, Abdelkareem MM, et al. Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients. Endocrinol Diabetes Metab 2023; 6: e394.","DOI":"10.1002\/edm2.394"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Mart\u00ednez-Gonz\u00e1lez MA, S\u00e1nchez-Villegas A. The emerging role of Mediterranean diets in cardiovascular epidemiology: monounsaturated fats, olive oil, red wine or the whole pattern? Eur J Epidemiol 2004; 19: 9\u201313.","DOI":"10.1023\/B:EJEP.0000013351.60227.7b"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Davis C, Bryan J, Hodgson J, Murphy K. Definition of the Mediterranean diet; a literature review. Nutrients 2015; 7: 9139\u20139153.","DOI":"10.3390\/nu7115459"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Fan H, Wang Y, Ren Z, et al. Mediterranean diet lowers all-cause and cardiovascular mortality for patients with metabolic syndrome. Diabetol Metab Syndr 2023; 15: 107.","DOI":"10.1186\/s13098-023-01052-7"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Becerra-Tom\u00e1s N, Blanco Mej\u00eda S, Viguiliouk E, et al. Mediterranean diet, cardiovascular disease and mortality in diabetes: a systematic review and meta-analysis of prospective cohort studies and randomized clinical trials. Crit Rev Food Sci Nutr 2020; 60: 1207\u20131227.","DOI":"10.1080\/10408398.2019.1565281"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Mart\u00edn-Pel\u00e1ez S, Fito M, Castaner O. Mediterranean diet effects on type 2 diabetes prevention, disease progression, and related mechanisms. A review. Nutrients 2020; 12: 2236.","DOI":"10.3390\/nu12082236"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Montemayor S, Bouzas C, Mascar\u00f3 CM, et al. Effect of dietary and lifestyle interventions on the amelioration of NAFLD in patients with metabolic syndrome: the FLIPAN study. Nutrients 2022; 14: 2223.","DOI":"10.3390\/nu14112223"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Katsagoni CN, Papatheodoridis GV, Ioannidou P, et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. Br J Nutr 2018; 120: 164\u2013175.","DOI":"10.1017\/S000711451800137X"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Vitaglione P, Savarese M, Paduano A, Scalfi L, Fogliano V, Sacchi R. Healthy virgin olive oil: a matter of bitterness. Crit Rev Food Sci Nutr 2015; 55: 1808\u20131818.","DOI":"10.1080\/10408398.2012.708685"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Ravaut G, L\u00e9giot A, Bergeron KF, Mounier C. Monounsaturated fatty acids in obesity-related inflammation. Int J Mol Sci 2020; 22: 330.","DOI":"10.3390\/ijms22010330"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Yang J, Fern\u00e1ndez-Galilea M, Mart\u00ednez-Fern\u00e1ndez L, et al. Oxidative stress and non-alcoholic fatty liver disease: effects of omega-3 fatty acid supplementation. Nutrients 2019; 11: 872.","DOI":"10.3390\/nu11040872"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Zhu Q, Li G, Ma L, et al. Virgin camellia seed oil improves glycolipid metabolism in the kidney of high fat-fed rats through AMPK-SREBP pathway. Nutrients 2023; 15: 4888.","DOI":"10.3390\/nu15234888"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505: 559\u2013563.","DOI":"10.1038\/nature12820"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Perler BK, Friedman ES, Wu GD. The role of the gut microbiota in the relationship between diet and human health. Annu Rev Physiol 2023; 85: 449\u2013468.","DOI":"10.1146\/annurev-physiol-031522-092054"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Marcelino G, Hiane PA, Freitas KC, et al. Effects of olive oil and its minor components on cardiovascular diseases, inflammation, and gut microbiota. Nutrients 2019; 11: 1826.","DOI":"10.3390\/nu11081826"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Meslier V, Laiola M, Roager HM, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. Gut 2020; 69: 1258\u20131268.","DOI":"10.1136\/gutjnl-2019-320438"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Tucker JM, Siegel R, Murray PJ, et al. Acceptability of time-limited eating in pediatric weight management. Front Endocrinol (Lausanne) 2022; 13: 811489.","DOI":"10.3389\/fendo.2022.811489"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Stanek A, Bro\u017cyna-Tkaczyk K, Zolghadri S, Cholewka A, My\u015bli\u0144ski W. The role of intermittent energy restriction diet on metabolic profile and weight loss among obese adults. Nutrients 2022; 14: 1509.","DOI":"10.3390\/nu14071509"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Katsarou AL, Katsilambros NL, Koliaki CC. Intermittent energy restriction, weight loss and cardiometabolic risk: a critical appraisal of evidence in humans. Healthcare (Basel) 2021; 9: 495.","DOI":"10.3390\/healthcare9050495"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Zhang X, Zou Q, Zhao B, et al. Effects of alternate-day fasting, time-restricted fasting and intermittent energy restriction DSS-induced on colitis and behavioral disorders. Redox Biol 2020; 32: 101535.","DOI":"10.1016\/j.redox.2020.101535"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Yin Z, Klionsky DJ. Intermittent time-restricted feeding promotes longevity through circadian autophagy. Autophagy 2022; 18: 471\u2013472.","DOI":"10.1080\/15548627.2022.2039524"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Pan C, Herrero-Fernandez B, Borja Almarcha C, et al. Time-restricted feeding enhances early atherosclerosis in hypercholesterolemic mice. Circulation 2023; 147: 774\u2013777.","DOI":"10.1161\/CIRCULATIONAHA.122.063184"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Ye Y, Xu H, Xie Z, et al. Time-restricted feeding reduces the detrimental effects of a high-fat diet, possibly by modulating the circadian rhythm of hepatic lipid metabolism and gut microbiota. Front Nutr 2020; 7: 596285.","DOI":"10.3389\/fnut.2020.596285"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Kord-Varkaneh H, Salehi-Sahlabadi A, Tinsley GM, Santos HO, Hekmatdoost A. Effects of time-restricted feeding (16\/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: a randomized controlled trial. Nutrition 2023; 105: 111847.","DOI":"10.1016\/j.nut.2022.111847"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Glick-Bauer M, Yeh MC. The health advantage of a vegan diet: exploring the gut microbiota connection. Nutrients 2014; 6: 4822\u20134838.","DOI":"10.3390\/nu6114822"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Klimenko NS, Tyakht AV, Popenko AS, et al. Microbiome responses to an uncontrolled short-term diet intervention in the frame of the citizen science project. Nutrients 2018; 10: 576.","DOI":"10.3390\/nu10050576"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Mart\u00ednez I, Lattimer JM, Hubach KL, et al. Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J 2013; 7: 269\u2013280.","DOI":"10.1038\/ismej.2012.104"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Federici E, Prete R, Lazzi C, et al. Bacterial composition, genotoxicity, and cytotoxicity of fecal samples from individuals consuming omnivorous or vegetarian diets. Front Microbiol 2017; 8: 300.","DOI":"10.3389\/fmicb.2017.00300"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Tomova A, Bukovsky I, Rembert E, et al. The effects of vegetarian and vegan diets on gut microbiota. Front Nutr 2019; 6: 47.","DOI":"10.3389\/fnut.2019.00047"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Losno EA, Sieferle K, Perez-Cueto FJA, Ritz C. Vegan diet and the gut microbiota composition in healthy adults. Nutrients 2021; 13: 2402.","DOI":"10.3390\/nu13072402"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Lloyd-Price J, Mahurkar A, Rahnavard G, et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature 2017; 550: 61\u201366.","DOI":"10.1038\/nature23889"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Wu G, Zhang C, Wu H, et al. Genomic microdiversity of <i>Bifidobacterium pseudocatenulatum<\/i> underlying differential strain-level responses to dietary carbohydrate intervention. mBio 2017; 8: e02348-16.","DOI":"10.1128\/mBio.02348-16"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 De Filippis F, Pasolli E, Tett A, et al. Distinct genetic and functional traits of human intestinal <i>prevotella copri<\/i> strains are associated with different habitual diets. Cell Host Microbe 2019; 25: 444\u2013453.e3.","DOI":"10.1016\/j.chom.2019.01.004"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675\u20131685.","DOI":"10.1056\/NEJMoa0907929"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Chen C, Liu Q, Liu L, Hu YY, Feng Q. Potential biological effects of (\u2212)-epigallocatechin-3-gallate on the treatment of nonalcoholic fatty liver disease. Mol Nutr Food Res 2018; 62: 1700483.","DOI":"10.1002\/mnfr.201700483"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 Clugston RD. Carotenoids and fatty liver disease: current knowledge and research gaps. Biochim Biophys Acta Mol Cell Biol Lipids 2020; 1865: 158597.","DOI":"10.1016\/j.bbalip.2019.158597"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Semmler G, Datz C, Reiberger T, Trauner M. Diet and exercise in NAFLD\/NASH: beyond the obvious. Liver Int 2021; 41: 2249\u20132268.","DOI":"10.1111\/liv.15024"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation. Eur J Sport Sci 2019; 19: 994\u20131003.","DOI":"10.1080\/17461391.2019.1571114"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Chen M, Zhu JY, Mu WJ, et al. Cdo1-Camkk2-AMPK axis confers the protective effects of exercise against NAFLD in mice. Nat Commun 2023; 14: 8391.","DOI":"10.1038\/s41467-023-44242-7"},{"key":"101","unstructured":"101 Jiaqian W, Changjun J, Yi P, Mi M, Junhan L. Study on the role of aerobic exercise in regulating the CNPY2-mediated AKT\/GSK3\u03b2 pathway for improving non-alcoholic fatty liver. Chinese Journal of Tissue Engineering Research 2025; 29: 6441\u20136448. (in Chinese)"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102 Peng H, Xiang J, Pan L, et al. METS-IR\/HOMA-IR and MAFLD in U.S. adults: dose-response correlation and the effect mediated by physical activity. BMC Endocr Disord 2024; 24: 132.","DOI":"10.1186\/s12902-024-01646-w"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103 Zhang HJ, He J, Pan LL, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern Med 2016; 176: 1074\u20131082.","DOI":"10.1001\/jamainternmed.2016.3202"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104 Keating SE, Sabag A, Hallsworth K, et al. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: a position statement from exercise and sport science australia. Sports Med 2023; 53: 2347\u20132371.","DOI":"10.1007\/s40279-023-01918-w"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105 Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc 2019; 51: 2375\u20132390.","DOI":"10.1249\/MSS.0000000000002116"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106 Campbell WW, Crim MC, Young VR, Evans WJ. Increased energy requirements and changes in body composition with resistance training in older adults. Am J Clin Nutr 1994; 60: 167\u2013175.","DOI":"10.1093\/ajcn\/60.2.167"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107 Hunter GR, Fisher G, Neumeier WH, Carter SJ, Plaisance EP. Exercise training and energy expenditure following weight loss. Med Sci Sports Exerc 2015; 47: 1950\u20131957.","DOI":"10.1249\/MSS.0000000000000622"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108 Stotzer US, Rodrigues MF, Domingos MM, et al. Resistance training suppresses intra-abdominal fatty acid synthesis in ovariectomized rats. Int J Sports Med 2015; 36: 226\u2013233.","DOI":"10.1055\/s-0034-1390494"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109 Heden T, Lox C, Rose P, Reid S, Kirk EP. One-set resistance training elevates energy expenditure for 72 h similar to three sets. Eur J Appl Physiol 2011; 111: 477\u2013484.","DOI":"10.1007\/s00421-010-1666-5"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110 Gao Y, Zhang W, Zeng LQ, et al. Exercise and dietary intervention ameliorate high-fat diet-induced NAFLD and liver aging by inducing lipophagy. Redox Biol 2020; 36: 101635.","DOI":"10.1016\/j.redox.2020.101635"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111 Yamamoto T, Takabatake Y, Takahashi A, et al. High-fat diet-induced lysosomal dysfunction and impaired autophagic flux contribute to lipotoxicity in the kidney. J Am Soc Nephrol 2017; 28: 1534\u20131551.","DOI":"10.1681\/ASN.2016070731"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112 Hajighasem A, Farzanegi P, Mazaheri Z. Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease. Arch Physiol Biochem 2019; 125: 142\u2013149.","DOI":"10.1080\/13813455.2018.1441872"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113 Zelber-Sagi S, Buch A, Yeshua H, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol 2014; 20: 4382\u20134392.","DOI":"10.3748\/wjg.v20.i15.4382"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114 Bacchi E, Negri C, Targher G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 2013; 58: 1287\u20131295.","DOI":"10.1002\/hep.26393"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115 Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 2017; 66: 142\u2013152.","DOI":"10.1016\/j.jhep.2016.08.023"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116 Slentz CA, Bateman LA, Willis LH, et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT\/RT. Am J Physiol Endocrinol Metab 2011; 301: E1033\u2013E1039.","DOI":"10.1152\/ajpendo.00291.2011"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117 Bateman LA, Slentz CA, Willis LH, et al. Comparison of aerobic versus resistance exercise training effects on metabolic syndrome (from the Studies of a Targeted Risk Reduction Intervention Through Defined Exercise - STRRIDE-AT\/RT). Am J Cardiol 2011; 108: 838\u2013844.","DOI":"10.1016\/j.amjcard.2011.04.037"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118 Noakes TD, Windt J. Evidence that supports the prescription of low-carbohydrate high-fat diets: a narrative review. Br J Sports Med 2017; 51: 133\u2013139.","DOI":"10.1136\/bjsports-2016-096491"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119 Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013; 59: 138\u2013143.","DOI":"10.1016\/j.jhep.2013.02.012"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120 Mart\u00ednez-Gonz\u00e1lez M\u00c1, Hern\u00e1ndez Hern\u00e1ndez A. Effect of the Mediterranean diet in cardiovascular prevention. Rev Esp Cardiol (Engl Ed) 2024; 77: 574\u2013582.","DOI":"10.1016\/j.rec.2024.01.006"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121 Kani AH, Alavian SM, Esmaillzadeh A, Adibi P, Haghighatdoost F, Azadbakht L. Effects of a low-calorie, low-carbohydrate soy containing diet on systemic inflammation among patients with nonalcoholic fatty liver disease: a parallel randomized clinical trial. Horm Metab Res 2017; 49: 687\u2013692.","DOI":"10.1055\/s-0042-118707"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122 Hsu CC, Ness E, Kowdley KV. Nutritional approaches to achieve weight loss in nonalcoholic fatty liver disease. Adv Nutr 2017; 8: 253\u2013265.","DOI":"10.3945\/an.116.013730"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123 Golabi P, Locklear CT, Austin P, et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: systematic review. World J Gastroenterol 2016; 22: 6318\u20136327.","DOI":"10.3748\/wjg.v22.i27.6318"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124 Eckard C, Cole R, Lockwood J, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Ther Adv Gastroenterol 2013; 6: 249\u2013259.","DOI":"10.1177\/1756283X13484078"},{"key":"125","unstructured":"125 Zhang C, Qu X. Effects of ketogenic diet combined with exercise rehabilitation training on lipid metabolism and liver function in patients with nonalcoholic fatty liver disease. Reflexology and Rehabilitation Medicine 2024; 5: 80\u201382+94. (in Chinese)"},{"key":"126","unstructured":"126 Yin L, MIngxing H. Effects of exercise prescription combined with diet intervention on body shape and blood biochemical indexes of patients with nonalcoholic fatty liver disease. Chinese Journal of Prevention and Control of Chronic Diseases 2021; 29: 115\u2013118. (in Chinese)"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127 Zannad F, Sanyal AJ, Butler J, Miller V, Harrison SA. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nat Med 2024; 30: 2423\u20132431.","DOI":"10.1038\/s41591-024-03223-z"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128 Huang WC, Xu JW, Li S, Ng XE, Tung YT. Effects of exercise on high-fat diet-induced non-alcoholic fatty liver disease and lipid metabolism in ApoE knockout mice. Nutr Metab (Lond) 2022; 19: 10.","DOI":"10.1186\/s12986-022-00644-w"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129 Silva AM, J\u00fadice PB, Carra\u00e7a EV, King N, Teixeira PJ, Sardinha LB. What is the effect of diet and\/or exercise interventions on behavioural compensation in non-exercise physical activity and related energy expenditure of free-living adults? A systematic review. Br J Nutr 2018; 119: 1327\u20131345.","DOI":"10.1017\/S000711451800096X"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130 Del Bo&apos; C, Perna S, Allehdan S, et al. Does the mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and meta-analysis of randomized control trials. Nutrients 2023; 15: 2250.","DOI":"10.3390\/nu15102250"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131 Glass O, Filozof C, Noureddin M, et al. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: recommendations from the Liver Forum. J Hepatol 2020; 73: 680\u2013693.","DOI":"10.1016\/j.jhep.2020.04.030"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132 Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne) 2023; 13: 1087260.","DOI":"10.3389\/fendo.2022.1087260"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133 Hannah WN,  Jr., Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis 2016; 20: 339\u2013350.","DOI":"10.1016\/j.cld.2015.10.008"},{"key":"134","unstructured":"134 Yang R, Wang L. Influence of lifestyle habits on nonalcoholic fatty liver disease. Scientia Sinica (Vitae) 2024; 54: 819\u2013830. (in Chinese)"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/79\/1\/79_25-259\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:34:02Z","timestamp":1783139642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/79\/1\/79_25-259\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.25-259","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"25-259"}}